BACKGROUND: The effectiveness of traditional adherence measurements used in adolescent populations is difficult to assess. Antiretroviral (ARV) adherence research among adolescents living with HIV in resource-constrained countries is particularly challenging and little evidence is available. OBJECTIVES: The primary objective of this study was to determine the feasibility of a large-scale, long-term study using electronic adherence monitoring in Uganda. The secondary objective was to compare accuracy of pill count (PC) and self-report (SR) adherence with electronic medication vials (eCAPs™). METHODS: Adolescents receiving ARV therapy at the Joint Clinical Research Centre in Kampala, Uganda, were recruited. ARVs were dispensed in eCAPs™ for 1 year. Person-pill-days (PPDs) [1 day where adherence was measured for one medication in one patient] were calculated and a weighted paired t-test was used to compare the levels of adherence among subjects for three different adherence measurement methods. RESULTS: Fifteen patients were included: 40% were female, mean age was 14 years, mean baseline CD4+ cell count was 244 cells/μL, and average treatment duration was 9 months at study entry. Overall, 4721 PPDs were observed. Some eCAPs™ required replacement during the study resulting in some data loss. Consent rate was high (94%) but was slow due to age limit cut-points. Overall adherence for SR was 99%, PC was 97% and eCAP™ was 88% (p<0.05 for all comparisons). 93%, 67% and 23% of patients had an adherence of greater than 95% as measured by SR, PC and eCAP™ methods, respectively. CONCLUSIONS: A large-scale adherence study in Uganda would be feasible using a more robust electronic monitoring system. Adherence measurements produced by PCs and self-reporting methods appear to overestimate adherence measured electronically.
BACKGROUND: The effectiveness of traditional adherence measurements used in adolescent populations is difficult to assess. Antiretroviral (ARV) adherence research among adolescents living with HIV in resource-constrained countries is particularly challenging and little evidence is available. OBJECTIVES: The primary objective of this study was to determine the feasibility of a large-scale, long-term study using electronic adherence monitoring in Uganda. The secondary objective was to compare accuracy of pill count (PC) and self-report (SR) adherence with electronic medication vials (eCAPs™). METHODS: Adolescents receiving ARV therapy at the Joint Clinical Research Centre in Kampala, Uganda, were recruited. ARVs were dispensed in eCAPs™ for 1 year. Person-pill-days (PPDs) [1 day where adherence was measured for one medication in one patient] were calculated and a weighted paired t-test was used to compare the levels of adherence among subjects for three different adherence measurement methods. RESULTS: Fifteen patients were included: 40% were female, mean age was 14 years, mean baseline CD4+ cell count was 244 cells/μL, and average treatment duration was 9 months at study entry. Overall, 4721 PPDs were observed. Some eCAPs™ required replacement during the study resulting in some data loss. Consent rate was high (94%) but was slow due to age limit cut-points. Overall adherence for SR was 99%, PC was 97% and eCAP™ was 88% (p<0.05 for all comparisons). 93%, 67% and 23% of patients had an adherence of greater than 95% as measured by SR, PC and eCAP™ methods, respectively. CONCLUSIONS: A large-scale adherence study in Uganda would be feasible using a more robust electronic monitoring system. Adherence measurements produced by PCs and self-reporting methods appear to overestimate adherence measured electronically.
Authors: Winnie Bikaako-Kajura; Emmanuel Luyirika; David W Purcell; Julia Downing; Frank Kaharuza; Jonathan Mermin; Samuel Malamba; Rebecca Bunnell Journal: AIDS Behav Date: 2006-07
Authors: Staci Martin; Deborah K Elliott-DeSorbo; Pamela L Wolters; Mary Anne Toledo-Tamula; Gregg Roby; Steve Zeichner; Lauren V Wood Journal: Pediatr Infect Dis J Date: 2007-01 Impact factor: 2.129
Authors: Marc Twagirumukiza; Pierre Claver Kayumba; Jan G Kips; Bernard Vrijens; Robert Vander Stichele; Chris Vervaet; Jean Paul Remon; M Luc Van Bortel Journal: Malar J Date: 2010-07-16 Impact factor: 2.979
Authors: Alexandra D Müller; Stefan Bode; Landon Myer; Paul Roux; Nicole von Steinbüchel Journal: Pediatr Infect Dis J Date: 2008-03 Impact factor: 2.129
Authors: Celestin Bakanda; Josephine Birungi; Robert Mwesigwa; Jean B Nachega; Keith Chan; Alexis Palmer; Nathan Ford; Edward J Mills Journal: PLoS One Date: 2011-04-29 Impact factor: 3.240
Authors: Matthew D Hickey; Charles R Salmen; Robert A Tessler; Dan Omollo; Peter Bacchetti; Richard Magerenge; Brian Mattah; Marcus R Salmen; Daniel Zoughbie; Kathryn J Fiorella; Elvin Geng; Betty Njoroge; Chengshi Jin; Yong Huang; Elizabeth A Bukusi; Craig R Cohen; Monica Gandhi Journal: J Acquir Immune Defic Syndr Date: 2014-07-01 Impact factor: 3.731
Authors: Julie A Denison; Harry Banda; Alexis C Dennis; Catherine Packer; Namakau Nyambe; Randy M Stalter; Jonathan K Mwansa; Patrick Katayamoyo; Donna R McCarraher Journal: J Int AIDS Soc Date: 2015-01-13 Impact factor: 5.396
Authors: Jasmine Buttolph; Irene Inwani; Kawango Agot; Charles M Cleland; Peter Cherutich; James N Kiarie; Alfred Osoti; Connie L Celum; Jared M Baeten; Ruth Nduati; John Kinuthia; Timothy B Hallett; Ramzi Alsallaq; Ann E Kurth Journal: JMIR Res Protoc Date: 2017-03-08
Authors: Samuel Kizito; Flavia Namuwonge; Rachel Brathwaite; Torsten B Neilands; Proscovia Nabunya; Ozge Sensoy Bahar; Christopher Damulira; Abel Mwebembezi; Claude Mellins; Mary M McKay; Fred M Ssewamala Journal: J Int AIDS Soc Date: 2022-09 Impact factor: 6.707
Authors: Olurotimi A Adejumo; Kathleen M Malee; Patrick Ryscavage; Scott J Hunter; Babafemi O Taiwo Journal: J Int AIDS Soc Date: 2015-09-16 Impact factor: 5.396